Navigation Links
Celtic Pharma Holdings Announces Investment in Novacta Biosystems Limited
Date:7/5/2009

ST PETER PORT, Guernsey and LONDON, July 6 /PRNewswire/ --

- GBP13.1 Million Funding to Drive Novel Antibiotics Platform Addressing Areas of Major Unmet Need, Including Hospital Acquired Infections C. Difficile and MRSA

Celtic Pharma Holdings Advisors LLP ("CPHA"), the advisor to the second Celtic Pharma fund, Celtic Pharma Holdings II LP ("CP2"), today announces its investment in a majority shareholding in Novacta Biosystems Limited ("Novacta"), which is developing a portfolio of antibiotics. The total being raised is GBP13.1m ($21.6m), payable against pre-agreed milestones. As part of this investment certain existing investors are re-investing.

Novacta is a UK-based company developing novel, naturally-derived products known as 'lantibiotics' as potential drugs. Lantibiotics have potent anti-infective properties but have historically been underexploited owing to a lack of research tools, a challenge that Novacta has successfully addressed through its proprietary technology platform. The most advanced programme will enter the clinic next year to treat infections caused by Clostridium difficile ("C. difficile"). The Wellcome Trust has provided in the order of GBP4m of translational funding to Novacta since 2004 for the development of the platform technology and more recently the C. difficile programme.

New anti-infective drugs are needed to target C. difficile without depleting other beneficial bacteria in the gut and preclinical data show that Novacta's lead lantibiotics selectively kill C. difficile with less disturbance of normal gut bacteria than seen with existing drugs. C. difficile infections (CDIs) are a serious problem: the number of cases grew by 22 percent in the UK last year, accounting for twice as many deaths as MRSA.

Novacta's pipeline also includes programmes targeting other areas of unmet medical need in bacterial infection. These include novel prom
'/>"/>

SOURCE Celtic Pharma Holdings Advisors LLP
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Neurobiological Technologies Partner, Celtic Pharma, Provides Update on XERECEPT(R) Clinical Program and Planned Sale in 2009
2. iCardiac Selected by Top 10 Pharmaceutical Company
3. WuXi PharmaTech Receives Award from BASF
4. Morphotek(R), Inc. Announces a Research Collaboration Agreement with Synageva BioPharma Corporation to Develop Potential Treatments for Cancer and Infectious Disease
5. NeoStem Raises Additional Funds from Principals of Suzhou Erye Pharmaceuticals Company Ltd. and U.S. Institutional and Private Investors, Bringing the Total Recent Financings to Over $15 Million; Funds Will Support Expansion Activities in the United State
6. Particle Sciences and Microfluidics Collaborate to Share Formulation and Nanotechnology Expertise for Pharmaceutical Drug Product Development, Analysis and Commercialization
7. Rib-X Pharmaceuticals, Inc. Appoints Dr. Russell Greig to Board of Directors
8. OncoGenex Pharmaceuticals Added to Russell Indexes
9. Asia Debut for Money-Saving Pharma-Packaging Machines from Ireland
10. Pharmaxis Closes Share Purchase Plan
11. ADVENTRX Pharmaceuticals Announces Plans for Remainder of 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2014)... The Europe Thermal Protective Clothing market ... crucial revenue forecasts. It estimates the market to ... CAGR of 7.5%, from 2013 to 2018. , ... Protective Clothing market report for a glimpse of ... various tables and figures. , http://www.micromarketmonitor.com/market/europe-thermal-protective-clothing-5957050557.html ...
(Date:11/27/2014)... -- First articles published now available ... Elsevier , a world-leading provider of scientific, technical and ... the launch of a new journal: Extreme ... launch of Extreme Mechanics Letters is driven ... applied sciences such as micro and nanotechnologies, biotechnologies, soft ...
(Date:11/26/2014)... 2014 (PRWEB) November 26, 2014 Publicis ... network, today announced the organization has won a total ... Awards. Digitas Health LifeBrands was honored with a Silver ... PHCG agencies received eight Awards of Excellence. , ... of pharmaceutical advertising and promotion. The Awards provide a ...
(Date:11/26/2014)... November 26, 2014 The North ... segments the market for detailed analysis of the ... market to reach $616.3 million by 2018, growing ... 2018. , Browse through the TOC of the ... get an idea of the in-depth analysis and ...
Breaking Biology Technology:The Europe Thermal Protective Clothing market is estimated to grow up to $577.9 million by 2018 - Report by MicroMarket Monitor 2The Europe Thermal Protective Clothing market is estimated to grow up to $577.9 million by 2018 - Report by MicroMarket Monitor 3Elsevier Announces the Launch of a New Journal: Extreme Mechanics Letters 2Elsevier Announces the Launch of a New Journal: Extreme Mechanics Letters 3Publicis Healthcare Wins 20 Rx Club Awards 2Publicis Healthcare Wins 20 Rx Club Awards 3The North America Thermal Protective Clothing Market is estimated to grow up to $616.3 million by 2018 - Report by MicroMarket Monitor 2The North America Thermal Protective Clothing Market is estimated to grow up to $616.3 million by 2018 - Report by MicroMarket Monitor 3
... Loramyc(R) Completes Patient Enrollment Ahead ... Zensana(TM) Reformulation Complete, Resubmission on Target, WOODCLIFF ... (NYSE: PRX ) today provided an update ... pipeline,products: pafuramidine, Loramyc(R) (miconazole Lauriad(R)), and Zensana(TM),(ondansetron). These ...
... Schering-Plough,Corporation (NYSE: SGP ) will provide a ... Hassan, chairman and chief executive officer, followed,by a ... Conference on Jan. 3, 2008, at approximately 8:45 ... "unplugged" presentation., Included in Mr. Hassan,s comments ...
... Schering-Plough,Corporation (NYSE: SGP ) is scheduled to ... quarter and full year on Tuesday, Feb. 12,2008., ... conduct a conference,call to review results for the 2007 ... and CEO, and other members of management,will host the ...
Cached Biology Technology:Strativa Pharmaceuticals, the Proprietary Products Division of Par Pharmaceutical, Provides an Update on Development Status of Pafuramidine and Other in-Licensed Products 2Strativa Pharmaceuticals, the Proprietary Products Division of Par Pharmaceutical, Provides an Update on Development Status of Pafuramidine and Other in-Licensed Products 3Strativa Pharmaceuticals, the Proprietary Products Division of Par Pharmaceutical, Provides an Update on Development Status of Pafuramidine and Other in-Licensed Products 4Strativa Pharmaceuticals, the Proprietary Products Division of Par Pharmaceutical, Provides an Update on Development Status of Pafuramidine and Other in-Licensed Products 5Schering-Plough to Webcast Presentation at Morgan Stanley Pharmaceutical CEOs Unplugged Conference 2Schering-Plough Schedules Conference Call and Webcast for 2007 Fourth Quarter, Full-Year Financial Result 2
(Date:11/5/2014)... of biology in the UTSA College of Sciences, ... selected to receive a two-year $300,00 National Science ... (EAGER). The funding supports President Obama,s BRAIN Initiative, ... new technology that will demystify complex brain processes. ... neuroscience are broken into the interactions of multiple ...
(Date:11/5/2014)... de Janeiro, Brazil -Individuals show great diversity in their ... males and females greatly differ in their perceptual evaluation ... of smell tests. , Sex differences in ... behaviors and may be connected to one,s perception of ... emotions. Thus, women,s olfactory superiority has been suggested to ...
(Date:11/4/2014)... the right time might actually help boost a species, ... in understanding animal populations, pest control and managing fish ... journal Trends in Ecology and Evolution , a ... kind of positive population effect an overall species experiences ... the size and developmental stage of the creatures that ...
Breaking Biology News(10 mins):UTSA biology professor awarded $300,000 NSF grant for brain research 2UTSA biology professor awarded $300,000 NSF grant for brain research 3The female nose always knows: Do women have more olfactory neurons? 2When less is more: Death in moderation boosts population density in nature 2
... of copying the body’s own natural "waste disposal" chemistry to ... percent of patients with urea cycle disorders --- most of ... New England Journal of Medicine summarizing a quarter century of ... phenylacetate and sodium benzoate, two chemicals the body already makes ...
... the government of The Gambia is encouraging citizens living ... to try an unproven herbal remedy. The HIV Medicine ... his unproven claims that the treatment "cures" AIDS. ... treatment to a handful of patients who had been ...
... isn’t such a good thing after all. , ... say they have confirmed what other scientists have only ... can help build stronger immune systems, and may protect ... that infants who were exposed to high levels of ...
Cached Biology News:An 'elegant' idea proves its worth 25 years later 2HIVMA opposes The Gambia's unproven AIDS remedy 2Early exposure to indoor fungus molecules may protect infants against future allergies 2